$TNDM

Tandem Diabetes Care Inc

  • NASDAQ
  • Health Technology
  • Medical Specialties
  • Manufacturing
  • Surgical and Medical Instrument Manufacturing

PRICE

$43.12 β–²0.865%

Extented Hours

VOLUME

588,235

DAY RANGE

42.04 - 43.525

52 WEEK

33.52 - 155.86

Join Discuss about TNDM with like-minded investors

profile
@dros #droscrew
recently

Upgrades 1/19: $ABB $AEG $AKAM $ARCO $ARWR $ASTR $ATVI $BBWI $BCC $BMO $CMC $CYRX $DXCM $EA $ENTG $GKOS $HWC $IBKR $KR $LVS $MBWM $OPRT $RKT $RMNI $SBNY $TFC $TNDM $TTWO $UAA $UL $XM $XOM

74 Replies 15 πŸ‘ 10 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Moderna ($MRNA) Q2 EPS $6.46 vs. est. $6.04; Q2 revs $4.4B vs. est. $4.28B; expects dose capacity for its covid-19 vaccine in fy 2021 to be between 800 mln and 1 bln doses; advance purchase agreements signed for expected product sales of $20 bln in 2021, including sales already recorded in 6 months ended June 30; signed agreements for $12 bln worth of sales for covid-19 vaccine in 2022, option for about $8 bln more; continue to expect $450 mln -$550 mln of capital investments for 2021 Cigna ($CI) Q2 adj EPS $5.24 vs. est. $4.96; Q2 revs $43.13B vs. est. $41.31B; pharmacy customer base at Q2 grew to 101.9M, an organic increase of 3.1M year to date; total medical customer base at Q2 was 17M, an increase of 279,000 customers YTD; Q2 profit overall fell -16% hurt by higher medical costs; backs year EPS but ups its rev guidance to at least $170B from $166B Nevro ($NVRO) slides after withdrawing FY forecast on COVID-19 concerns and guided Q3 sales between $90M-$93M which is below analyst estimates of $114.7M Regeneron Pharma ($REGN) phase 3 Trial of Libtayo combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Abiomed ($ABMD) Q1 adj EPS $1.10 vs. est. $1.05; Q1 revs $252.6M vs. est. $240.91M; raises FY22 revenue view to $1.03B-$1.05B from prior $990M-$1.03B (22%-24% growth); expects its fiscal year 2022 non-GAAP operating margin to be in the range of 24% to 26% Amedisys ($AMED) announces new $100M share repurchase program; Q2 adj EPS $1.69 vs. est. $1.67; Q2 revs $564.2M vs. est. $566.19M; guides 2021 adj EPS $6.37-$6.49 vs. est. $6.96; sees 2021 adj net service revenue $2.23B-$2.245B. Evolent Health ($EVH) 2Q EPS ($0.11) vs est. ($0.04) on revs $222.1Mm vs est. $216.9Mm; guides 3Q revs $215-230Mm vs est. $217.7Mm, sees FY revs $870-900Mm vs est. $870.8Mm; announces agreement to acquire Vital Decisions outstanding equity interests for aggregate price up to $130Mm, says transaction is accretive to EBITDA/share before synergies McKesson ($MCK) Q1 adj EPS $5.56 vs. est. $4.15; Q1 revs $62.7B vs. est. $59.99B; raises FY22 adj EPS view to $19.80-$20.40 from prior view $18.85-$19.45 (est. $19.23) 1life Healthcare, Inc. ($ONEM) Q2 EPS loss (-$0.30) vs. est. loss (-$0.20); Q2 revs $120.4M vs. est. $115.7M; sees Q3 revs $113M-$120M vs. est. $118M; sees year revs $475M-$485M vs. est. $482.3M; Membership count as of quarter-end was 621,000 compared to 475,000, a 31% increase; Adjusted EBITDA was positive $6.9 million, or 6% of net revenue Sarepta Therapeutics ($SRPT) Q2 non-GAAP EPS loss (-$1.52) vs. est. loss (-$1.26); net product sales for q2 reached $141.8 mln, a 27% increase over same quarter of prior year; raises full-year product revenue guidance by nearly $30 mln to between $565 mln to $575 mln Tandem Diabetes ($TNDM) 2Q revs $172.1Mm vs est. $143.4Mm; guides FY sales $670-685Mm vs est. $637Mm; guides FY adj EBITDA mgn about 15% vs est. 13.5% Industrials & Materials Albemarle ($ALB) Q2 adj EPS $0.89 vs. est. $0.83; Q2 revs $773.9M vs. est. $788.6M; qtrly lithium net sales of $320.3 mln increased $36.6 mln yoy primarily driven by higher volumes; full-year 2021 net sales guidance improved vs previous guidance primarily due to increased lithium sales, improving catalysts trends – sees year sales $3.3B-$3.4B vs. est. $3.24B Hillenbrand ($HI) 3Q adj EPS $0.85 vs est. $0.76 on revs $695Mm; guides 4Q adj EPS $0.82-0.92 vs est. $0.85, sees 4Q revs $713-738Mm vs est. $709.1Mm Maxar Technologies ($MAXR) 2Q EPS $0.60 vs est. $0.14 on revs $473Mm vs est. $441.5Mm Summit Materials ($SUM) 2Q EPS $0.48 vs est. $0.52 on revs $618.5Mm vs est. $647.1Mm; no change to FY guide Valvoline ($VVV) Q3 adj EPS $0.55 vs. est. $0.45; Q3 revs $792M vs. est. $745.32M; Q3 retail Services system-wide same-store sales grew 40.5%; Q3 same-store sales rose 27%; sees FY sales growth 25%-26% and FCF $250M-$270M Media & Telecom Fox Corp. ($FOXA) Q4 adj EPS $0.65 vs. est. $0.57; Q4 revs $2.89B vs. est. $2.75B; raises semi-annual dividend to 24c; cable network programming reported quarterly segment revenues of $1.40B, an increase of $128M; affiliate revenues increased 10% with 16% growth at the television segment and 6% growth at the cable network programming segment in q4 Roku Inc. ($ROKU) Q2 EPS 52c vs est. 13c on revs $645M vs est. $618.4M, average rev per user $36.46 (+46% YoY), active accounts 55.1M vs est. 55.8M; at midpoint of Q3 guidance, sees revs $675M-$685M vs est. $645M, gross profit $315M-$325M, adj EBITDA $60M-$70M, net income (-$3M)-$7M, anticipates sequential increases in operating expenses in 2H from investments in headcount, product development, and sales & marketing Technology Amdocs Ltd. ($DOX) 3Q adj EPS $1.35 vs est. $1.18 on revs $1.066B vs est. $1.06B; guides 4Q adj EPS $1.13-1.19 vs est. $1.28, sees 4Q revs $1.065-1.105B vs est. $1.087B Booking Holdings ($BKNG) 2Q adj EPS ($2.55) vs est. ($2.04) on revs $2.2B vs est. $1.9B, encouraged by sequential improvement in booking trends with 2Q room nights +59% vs 1Q; said in in q2, we saw the first sequential increase in the number of properties on booking.com and lowest number of properties coming off of our platform since the onset of the covid-19 pandemic DXC Technology ($DXC) Q1 adj EPS $0.84 vs. est. $0.74; Q1 revs $4.14B vs. est. $4.11B; Q2 guidance falls short of views but backs year EPS view $3.45-$3.65 vs. est. $3.56 and backs FY22 revenue view $16.6B-$16.8B (est. $16.74B); Bookings of $4.6 billion and book-to-bill ratio of 1.12x in Q1 FY22 Electronic Arts ($EA) Q1 EPS $0.71 vs. est. $0.62; Q1 net bookings $1.336B vs. est. $1.28B; sees Q2 EPS roughly $0.36 vs. est. $1.07; sees Q2 net bookings $1.725B vs. est. $1.62B; raises FY22 EPS view to $1.58 from $1.34 and ups FY21 bookings view to $7.4B from $7.3B Fastly Inc. ($FSLY) shares fall -18%; Q2 adj EPS ($$0.15) vs est. ($0.17) on revs $85.03M vs est. $85.7M, sees Q3 EPS loss (21c)-(18c) vs est. (18c) on revs $82M-$85M vs est. $97.9M, and forecasts FY EPS (65c)-(57c) vs est. (43c) on revs $340M-$350M vs est. $382.5M GoDaddy ($GDDY) Q2 EPS $0.27 vs. est. $0.32; Q2 revs $931.3M vs. est. $919.7M; total bookings of $1.055B, up 12.7% year over year, or 10.6% on a constant currency basis; Domains revenue of $436.7 million, up 18.2% yoy; Hosting and presence revenue of $318.5 million, up 9.0% yoy; Business applications revenue of $176.1 million, up 21.8% yoy; sees year revs $3.75B, in-line HubSpot ($HUBS) 2Q adj EPS $0.43 vs est. $0.32 on revs $310.8Mm vs est. $296Mm; guides 3Q adj EPS $0.42-0.44 vs est. $0.39, sees 3Q revs $325-327Mm vs est. $318.7Mm; guides FY revs $1.268-1.272B vs est. $1.244B MercadoLibre ($MELI) Q2 EPS $1.37 vs est. $0.19 on revs $1.7B vs est. $1.48B with commerce revs +96.4% YoY and fintech revs +88.9%; unique active users 75.9M in quarter (+47.4% YoY), total payment volume through Mercado Pago topped $17.5B (+56.3% in USD), gross merchandise volume $7B (+39.2% in USD) Ping Identity ($PING) 2Q adj EPS $0.11 vs est. $0.04 on revs $78.9Mm vs est. $66.1Mm; guides 3Q revs $65-70Mm vs est. $65.1Mm, sees 3Q total ARR $286-288Mm; guides FY revs $278-285Mm vs est. $269.3Mm, sees FY total ARR $304-306Mm Qorvo ($QRVO) Q1 EPS $2.83 vs. est. $2.45; Q1 revs $1.11B vs. est. $1.08B; sees Q2 EPS $3.24 at midpoint vs. est. $3.02; sees Q2 revenue $1.24B-$1.26B vs. est. $1.21B Trimble Inc. ($TRMB) Q2 adj EPS $0.72 vs. est. $0.59; Q2 revs $945.3M vs. est. $867.8M; sees FY21 adj EPS $2.45-$2.65 vs. est. $2.45; sees FY21 adjusted revenue $3.55B-$3.65B vs. est. $3.48B; Q2 annualized recurring revenue (ARR) was $1.35 billion, up 11% yoy Western Digital ($WDC) 4Q adj EPS $2.16 vs est. $1.51 on revs $4.9B vs est. $4.55B; guides 1Q revs $4.9-5.1B vs est. $4.9B, sees 1Q adj EPS $2.25-2.55 vs est. $2.05

98 Replies 8 πŸ‘ 8 πŸ”₯

profile
@thegiz18 #ivtrades
recently

Tonights earnings include $ETSY, $FSLY, $FLT, $FMC, $GDOT, $MET, $PYPL, $RKT, $SBRA, $SRPT, $TNDM, $SKT, $UBER

146 Replies 11 πŸ‘ 7 πŸ”₯

profile
@Benlax #droscrew
recently

woah $TNDM guess who theyre partnered with $DXCM

70 Replies 6 πŸ‘ 10 πŸ”₯

profile
@zonatrading #Zona Trading
recently

Me gusta $TNDM acabo de meterle LCS

46 Replies 10 πŸ‘ 7 πŸ”₯

profile
@sebastiandv #Zona Trading
recently

sali de $tndm ayer

72 Replies 8 πŸ‘ 12 πŸ”₯

profile
@RedSunCap #droscrew
recently

grabbing $TNDM here

109 Replies 8 πŸ‘ 13 πŸ”₯

profile
@zonatrading #Zona Trading
recently

$TNDM es un downtrend para mΓ­ tambien

144 Replies 12 πŸ‘ 11 πŸ”₯

profile
@sebastiandv #Zona Trading
recently

$TNDM como la ven, con confirmacion en par de dias?

130 Replies 14 πŸ‘ 15 πŸ”₯

profile
@Navneet #droscrew
recently

$tndm 100 calls flow jan 2021

83 Replies 13 πŸ‘ 8 πŸ”₯

profile
@RedSunCap #droscrew
recently

TNDM Looking sexual

130 Replies 11 πŸ‘ 11 πŸ”₯

profile
@Snowcow #droscrew
recently

$TNDM is nice

56 Replies 15 πŸ‘ 12 πŸ”₯

profile
@RedSunCap #ivtrades
recently

@ivtrades-Chris $TNDM got your name all over it

110 Replies 10 πŸ‘ 13 πŸ”₯

profile
@RedSunCap #droscrew
recently

$TNDM - that perfect Mean reversion play

137 Replies 12 πŸ‘ 6 πŸ”₯

profile
@dros #droscrew
recently

300 $TNDM JAN2022 $120 Cs bought 12.10

100 Replies 6 πŸ‘ 12 πŸ”₯

profile
@dros #droscrew
recently

300 $TNDM JAN2022 $120 Cs bought 12.10

108 Replies 12 πŸ‘ 12 πŸ”₯

profile
@RedSunCap #droscrew
recently

TNDM with a nice bar

122 Replies 12 πŸ‘ 13 πŸ”₯

profile
@dros #droscrew
recently

TNDM still strong, fresh session highs

77 Replies 12 πŸ‘ 6 πŸ”₯

profile
@RedSunCap #droscrew
recently

i missed that TNDM entry

100 Replies 9 πŸ‘ 11 πŸ”₯

profile
@dros #droscrew
recently

$TNDM strong like bull

75 Replies 7 πŸ‘ 15 πŸ”₯

profile
@RedSunCap #droscrew
recently

that TNDM flow was nice

64 Replies 14 πŸ‘ 6 πŸ”₯

profile
@Benlax #droscrew
recently

that TNDM is nice

51 Replies 6 πŸ‘ 8 πŸ”₯

profile
@RedSunCap #droscrew
recently

TNDM is real nice

49 Replies 15 πŸ‘ 14 πŸ”₯

profile
@dros #droscrew
recently

972 $TNDM JAN2021 $115 Cs bought 10.605

116 Replies 11 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

972 $TNDM JAN2021 $115 Cs bought 10.605

81 Replies 7 πŸ‘ 9 πŸ”₯

profile
@thegiz18 #ivtrades
recently

After close are the big boys $AAPL, $AMZN, $FB, $GOOGL, $GILD, $F, $EXPE, $EA, $SHAK, $TEAM, $MGM, $VRTX, $X, $TNDM, $EXAS along with a slew of others

147 Replies 14 πŸ‘ 15 πŸ”₯

profile
@Benlax #droscrew
recently

$TNDM $DXCM

83 Replies 15 πŸ‘ 13 πŸ”₯

profile
@Benlax #droscrew
recently

taking off most $TNDM shares here, 32%

106 Replies 13 πŸ‘ 11 πŸ”₯

profile
@zonatrading #Zona Trading
recently

Creo que voy a cerrar $TNDM

74 Replies 7 πŸ‘ 9 πŸ”₯

profile
@Benlax #droscrew
recently

$TNDM surprise boost following indirect acknowledgment that $UNH will cover t:slim pump. Piper Sandler analyst sees easier access to TNDM pumps will likely lead to significantly more uptake from this group of patients.

147 Replies 15 πŸ‘ 10 πŸ”₯

profile
@Benlax #droscrew
recently

idk if you saw the $TNDM news but $UNH now covering their pumps

112 Replies 7 πŸ‘ 7 πŸ”₯

profile
@zonatrading #Zona Trading
recently

$TNDM se me esta dando como los dioses

113 Replies 7 πŸ‘ 12 πŸ”₯

profile
@zonatrading #Zona Trading
recently

$TNDM va muy bien no se si alguien la agarro conmigo.

57 Replies 12 πŸ‘ 9 πŸ”₯

profile
@zonatrading #Zona Trading
recently

Estoy en TNDM, vendi 1/4 parte en 92

116 Replies 8 πŸ‘ 13 πŸ”₯

profile
@zonatrading #Zona Trading
recently

TNDM rompΓ­o tamben

80 Replies 13 πŸ‘ 14 πŸ”₯

profile
@zonatrading #Zona Trading
recently

$TNDM, me gusta el patrΓ³n, hay que medir bien el risk management ya que tiene ATR alto.

107 Replies 9 πŸ‘ 11 πŸ”₯

Key Metrics

Market Cap

2.75 B

Beta

1.62

Avg. Volume

1.28 M

Shares Outstanding

64.30 M

Yield

0%

Public Float

0

Next Earnings Date

2023-02-22

Next Dividend Date

Company Information

Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2β„’ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

CEO: John Sheridan

Website:

HQ: 11075 Roselle St San Diego, 92121-1204 California

Related News